Current Radiopharmaceuticals

Editor-in-Chief

Andrea Ciarmiello
Chief of Nuclear Medicine Unit and Imaging Department
S. Andrea Hospital
La Spezia
(Italy)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 1 Issue: 3, September

Editorial [Hot topic:Targeted Alpha Particle Therapy (Guest Editors: Ganesan Vaidyanathan and Roy Larsen)]

Volume:1   Issue: 3
Pp: 125-126
GANESAN VAIDYANATHAN and ROY H. LARSEN
DOI: 10.2174/1874471010801030125
Published on: 01 March, 2012

Commercial Availability of Alpha-Emitting Radionuclides for Medicine

Volume:1   Issue: 3
Pp: 127-134
Darrell R. Fisher
DOI: 10.2174/1874471010801030127
Published on: 01 March, 2012

Production of Alpha Emitters for Targeted Alpha Therapy

Volume:1   Issue: 3
Pp: 135-143
A. Morgenstern, K. Abbas, F. Bruchertseifer and C. Apostolidis
DOI: 10.2174/1874471010801030135
Published on: 01 March, 2012

Astatine Radiopharmaceuticals: Prospects and Problems

Volume:1   Issue: 3
Pp: 177-196
Ganesan Vaidyanathan and Michael R. Zalutsky
DOI: 10.2174/1874471010801030177
Published on: 01 March, 2012

Experimental Targeted Therapy Using [211At]meta-Astatobenzylguanidine and Transfection of the Noradrenaline Transporter Gene

Volume:1   Issue: 3
Pp: 197-202
M. Boyd, A. G. McCluskey, A. Sorensen and R. J. Mairs
DOI: 10.2174/1874471010801030197
Published on: 01 March, 2012

Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy open access plus

Volume:1   Issue: 3
Pp: 203-208
Oyvind S. Bruland, Thora J. Jonasdottir, Darrell R. Fisher and Roy H. Larsen
DOI: 10.2174/1874471010801030203
Published on: 01 March, 2012

Targeted Alpha-Particle Therapy with 227Th-Labeled Antibodies

Volume:1   Issue: 3
Pp: 209-214
Jostein Dahle and Roy H. Larsen
DOI: 10.2174/1874471010801030209
Published on: 01 March, 2012

Treatment of Diffuse-Type Gastric Cancer Cells Using 213Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination

Volume:1   Issue: 3
Pp: 215-224
Christof Seidl and Reingard Senekowitsch-Schmidtke
DOI: 10.2174/1874471010801030215
Published on: 01 March, 2012

Targeting EGFR and HER2 with 211At-Labeled Molecules: Unexpected and Expected Dose-Effect Relations in Cultured Tumor Cells

Volume:1   Issue: 3
Pp: 225-233
J. Carlsson, A. C. Steffen, A. L. Sundberg, M. Vikstrom, A. Orlova, L. Gedda, B. Stenerlow, H. Lundqvist and V. Tolmachev
DOI: 10.2174/1874471010801030225
Published on: 01 March, 2012

Radioimmunotherapy of Infection with 213Bi-Labeled Antibodies

Volume:1   Issue: 3
Pp: 234-239
Ekaterina Dadachova
DOI: 10.2174/1874471010801030234
Published on: 01 March, 2012

New Directions for Clinical Trials of Targeted Alpha Therapy for Metastatic Melanoma

Volume:1   Issue: 3
Pp: 240-250
Barry J. Allen, Chand Raja, Syed M.A. Rizvi, Peter Graham and John H. Kearsley
DOI: 10.2174/1874471010801030240
Published on: 01 March, 2012

Targeted α-Particle Therapy: A Clinical Overview open access plus

Volume:1   Issue: 3
Pp: 251-253
Massimo Salvatori, Luca Indovina and Luigi Mansi
DOI: 10.2174/1874471010801030251
Published on: 01 March, 2012